This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Cincinnati Children's Hospital Medical Center, Kurome Therapeutics, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2026.
Company Filing History:
1 out of 429 
1 out of 2 
1 out of 3,693 
Years Active: 2026
Title: Chris James Finocchio: Innovator in Pharmaceutical Compounds
Introduction
Chris James Finocchio is a notable inventor based in Virginia Beach, VA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific diseases. His innovative work has the potential to impact the treatment of various hematological conditions.
Latest Patents
Finocchio holds a patent for "Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof." This patent includes inventive compounds that inhibit IRAK and/or FLT3, which can be utilized in treating diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The patent outlines methods for administering these compounds, including their use in pharmaceutical compositions. Additionally, it discusses the potential for combining these innovative compounds with other cancer therapies to enhance treatment efficacy.
Career Highlights
Throughout his career, Finocchio has worked with esteemed organizations, including Cincinnati Children's Hospital Medical Center and the United States Department of Health and Human Services. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
One of his notable coworkers is Scott Bryan Hoyt, with whom he has likely shared insights and expertise in their respective fields. Their collaboration may have further advanced the research and development of innovative pharmaceutical solutions.
Conclusion
Chris James Finocchio is a distinguished inventor whose work in pharmaceutical compounds demonstrates a commitment to advancing medical treatments. His patent for IRAK and FLT3 inhibiting compounds showcases his innovative approach to addressing critical health challenges.